- Open Access
Overexpression of TMEM158 contributes to ovarian carcinogenesis
© Cheng et al. 2015
- Received: 28 April 2015
- Accepted: 17 July 2015
- Published: 4 August 2015
Transmembrane protein 158 (TMEM158) is a recently identified upregulated gene during Ras-induced senescence. Its association with various cancers has been recently reported. However, the expression and biological function of TMEM158 in ovarian cancer is still unclear. This study was aimed to elucidate the roles of TMEM158 in cell proliferation, adhesion and cell invasion of ovarian cancer cells.
We analyzed TMEM158 mRNA level in ovarian cancer tissues and adjacent no-tumorous tissues by real-time PCR. We then suppressed TMEM158 expression of ovarian cancer cells by RNA interference and examined the effects of TMEM158 knockdown on cancerous transformation of ovarian cancer cells.
The RNA-sequencing data of the ovarian cancer cohort from The Cancer Genome Atlas project (TCGA) and our real-time PCR data showed that TMEM158 was overexpressed in ovarian cancer. Knockdown of TMEM158 by RNA interference in ovarian cancer cells significantly inhibited cell proliferation, which may be due to the increase of G1-phase arrest. Silencing of TMEM158 also inhibited cell adhesion, cell invasion as well as tumorigenicity in nude mice. Moreover, knockdown of TMEM158 notably repressed cell adhesion via down-regulating the expression intercellular adhesion molecule1 (ICAM1) and vascular cell adhesion molecule1 (VCAM1). Transforming Growth Factor-β (TGF-β) signaling pathway was also remarkably impaired by TMEM158 silencing.
Our data suggests that TMEM158 may work as an oncogene for ovarian cancer and that inhibition of TMEM158 may be a therapeutic strategy for ovarian cancer.
- Ovarian cancer
- Cell invasion
- Cell adhesion
Ovarian cancer is the most lethal type of gynecologic malignancy . Due to its insidious onset, ovarian cancer is often diagnosed in advanced stages, resulting in a poor survival rate . The five-year survival of patients with ovarian cancer is almost 30 % and has not significantly changed over the past 30 years regardless of important advances in surgery, radiation and chemotherapy [3–7]. This emphasizes the need for new diagnosis markers and therapies based on a well understanding of the molecular mechanisms underlying the oncogenesis and development of ovarian cancer.
Transmembrane protein 158 (TMEM158) was identified as an upregulated gene during Ras-induced senescence in human diploid fibroblasts infected with a RasV12-containing retrovirus and also known as Ras-induced senescence 1(RIS-1) . In a non-small cell lung cancer (NSCLC) line transfected with the gene TLSC1, TMEM158 expression was found upregulated and tumor properties of the cells were suppressed . There are a few studies concerned about the expression and functions of TMEM158 in tumors [10–12]. Gene expression analysis of ductal carcinoma showed that TMEM158 expression was not detected in tumor cells, but its expression was observed in the immediately adjacent stromal cells . TMEM158 was overexpressed in Wilms tumors with somatic CTNNB1 mutations, suggesting a relationship between the Ras and Wnt signaling pathways . TMEM158 has recently been identified as a target gene in the mutator pathway of microsatellite instability (MSI)-positive colorectal cancers. Low frequency MSI tumors with TMEM158 mutated usually were associated with a worse prognosis . However, little is known about the expression pattern and biological functions of THEM158 in ovarian cancers.
To investigate the roles of TMEM158 in ovarian cancer, we determined its expression in ovarian cancer and normal tissues. The effects of TMEM158 knockdown in the proliferation, adhesion and invasion of ovarian cancer cells were assessed. The involved possible mechanism was also explored. Our study provides original documentation for the overexpression of TMEM158 in ovarian cancer and it may be an effective therapeutic target for this disease.
From The Cancer Genome Atlas (TCGA, https://tcga-data.nci.nih.gov/tcga/), we collect expression data of 568 ovarian cancers and 8 adjacent normal tissues. TMEM158 expression was shown to be statistically normally distributed by Shapiro-Wilk test. Levene’s test indicated heterogeneous variances of TMEM158 expression among ovarian cancers and normal tissues (P < 0.001).
To further investigate the biological pathways involved in ovarian cancer pathogenesis through TMEM158 pathway, we performed a gene set enrichment analysis (GSEA) [13, 14]. The KEGG gene sets biological process database (c2.KEGG.v4.0) were used for enrichment analysis.
Tumor tissues and paired noncancerous tissues were collected from 25 patients diagnosed with Stage II/III epithelial ovarian serous adenocarcinoma, who were admitted to Department of Obstetrics and Gynecology, Yangpu Hospital, Tongji University (Shanghai, China) between 2010 and 2013. Written informed consent was obtained from all patients prior to participation on the study. The ethics committee of Tongji University (Shanghai, China) approved the design and informed consent.
All culture media contained 10 % fetal bovine serum (FBS, Life Technologies), 100 mg/ml penicillin G, and 50 μg/ml streptomycin (Life Technologies). All cell lines were from American Type Culture Collection. The ovarian cancer cell lines OVCAR3, A2780 and HO-8910 cells were cultured in RPMI 1640 (Life Technologies). The CAOV3, SK-OV-3 and HEK 293T cells were cultured in DMEM (Life Technologies). All cells were maintained at 37 °C in 5 % CO2.
RNA extraction and Real-time PCR
Total RNA was extracted using TRIzol Reagent (Invitrogen) according to the manufacturer’s instructions. Complementary DNA was synthesized with CDNA synthesis kit (Thermo Fisher Scientific). Real-time PCR was performed to detect mRNA levels of indicated genes. GAPDH was served as an internal control. The primers used were list as follows: TMEM158, 5′-TGTGCTTCGTGCTGTAGTTATC-3′ and 5′- TCAGTCCAAGGGCTTAAACATC-3′; GAPDH, 5′- AATCCCATCACCATCTTC -3′ and 5′-AGGCTGTTGTCATACTTC-3′; transforming Growth Factor-β (TGF-β), 5′- GACTACTACGCCAAGGAGGTC-3′ and 5′-GAGAGCAACACGGGTTCAG-3′; bone morphogenetic protein 4 (BMP4), 5′- CTGACCACCTCAACTCAAC -3′ and 5′-ACCCACATCCCTCTACTAC -3′; intercellular adhesion molecule1 (ICAM1), 5′-GTTGTTGGGCATAGAGAC-3′ and 5′- CAGGGCAGTTTGAATAGC-3′; vascular cell adhesion molecule1 (VCAM1), 5′-TGGGAACGAACACTCTTAC-3′ and 5′- CAGCAACTGAACACTTGAC - 3′. All reactions were conducted on an ABI 7300 real-time PCR machine (Applied Biosystems) using the following cycling parameters, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s, 60 °C for 45 s. The gene expression was calculated using the ΔΔ Ct method. All data represent the average of three replicates.
RNA interference and construction of stable cell line
Three shRNAs targeting position 1520 − 1540 (AAATGACCAAATCCTGTGTAT; named TMEM158-Ri-1), position 1627 − 1647 (TAAGAGAAGCTCTTTGTATCT; named TMEM158-Ri-2) and position 1719 − 1739 (TAACACCGATATATTGTTACC; named TMEM158-Ri-3) of human TMEM158 mRNA were cloned into a lentiviral vector (PLKO.1). A non-specific scramble shRNA sequence (CCTAAGGTTAAGTCGCCCTCG) was used as negative control. The constructs were then transfected into HEK293T cells with lentiviral packaging vectors by using lipofectamine 2000 (Invitrogen) according to the manufacture’s instruction. Viruses were collected 48 h after transfection and used to infect A2780 cells and HO-8910 cells. Stable cell line was generated by puromycin (Sigma) selection.
Total cell lysates were collected with radioimmunoprecipitation assay buffer (50 mmol/l Tris-HCl, 150 mmol/l NaCl, 1 % Triton X-100, 0.1 % SDS, 1 % deoxycholic acid sodium). Protein concentration was measured by BCA protein assay kit (Thermo Fisher Scientific). The supernatants with equal amounts of protein were separated on SDS-PAGE gels followed by electroblotting to nitrocellulose membranes. Western blot analysis was then carried out with appropriate primary and horseradish peroxidase-conjugated secondary antibodies. Membranes were developed with enhanced chemiluminescence (Bio-Rad). Antibodies against TMEM158, TGFβ1, BMP4, ICAM1 and VCAM1 were purchased from Abcam. GAPDH antibody was from CST Biotech. (Danvers, MA, USA). GAPDH was served as an internal control. The band intensity was measured using ImageJ software (National Institutes of Health).
Cell proliferation assay
Cell proliferation was detected by using the Cell Count Kit-8 (CCK-8, Dojindo Laboratories). Briefly, indicated cells were plated onto 96-well plates (3 × 103 cells per well). At indicated time point, CCK8 solution (10 μl in 100μl DMEM medium) was added to each well and incubated for 1 h. Optical density values (OD) was measured at wavelength 450 nm by a microplate reader (Bio-Rad). Each assay was carried out in triplicate.
Cell cycle analysis
The cell cycle was evaluated by flow cytometry using propidium iodide (PI, Sigma, St. Louis, MO, USA) staining on a flow cytometer (BD Biosciences). Briefly, indicated cells were plated in 6-well plates. The cells were collected and fixed in 70 % ethanol at -20 °C overnight after 24 h culture. Cells were then washed in PBS and resuspended in staining solution containing 20 μg/ml PI and 200 μg/ml RNAse A. Experiments were performed in triplicate and 3 × 104 cells were analyzed per sample. G1, S, and G2/M fractions were quantified using CellQuest software (BD Biosciences) and manual gating. Each assay was carried out in triplicate.
Cell adhesion assay
The adhesion assay was performed in 12-well plates. The plates were pre-coated with 1 ml of fibronectin (5 μg/ml) for 2 h at room temperature. Cells were seeded into the coated plates at a density of 105 cells per well and allowed to adhere at 37 °C for 1 h. Nonadherent cells were washed off with phosphate-buffered saline (PBS) and fixed in 4 % paraformaldehyde and stained with GIEMSA solution. The number of adherent cells determined as described previously . Each assay was carried out in triplicate.
In vitro invasion assay
The upper well of the transwell (Corning, NY, USA) was coated with Matrigel (BD Biosciences) at 37 °C in a 5 % CO2 incubator for 1 h. Indicated cells were serum starved for 24 h, and then 500 μl of cell suspension containing 105 cells/ml were placed in the upper compartment of the chamber. Culture medium supplemented with 10 % FBS (750 μl) was added into the lower well of the chamber. The plates were incubated for 48 h. At the end of the incubation, the cells on the upper surface of the filter were completely removed by wiping with a cotton swab. Cells that migrated into the lower well were washed with PBS, fixed in 4 % paraformaldehyde and stained by 0.2 % crystal violet. Cells were photographed and counted under microscopy. Each assay was carried out in triplicate.
In vivo tumorigenicity assay
Male BALB/c nude mice aged 4 − 5 weeks old were purchased from Shanghai Laboratory Animal Company. The mice were housed in a pathogen-free animal facility and randomly assigned to the control or experimental group (five mice per group). For each cell line, 2 × 106 cells were resuspended in 200μl medium and subcutaneously injected into the nude mice. Tumor formation was monitored every three or four days by measuring the largest and the smallest diameter of the formed tumors, and the volume of the tumors was calculated using the following formula: volume = 1/2 × (largest diameter) × (smallest diameter)2. At euthanasia, the tumors were recovered and the wet weights of each tumor were examined. Animal care practices and all experiments were reviewed and approved by the Committee on the Ethics of Animal Experiments of Tongji University (Shanghai, China).
The data were analyzed using the two-tailed Student’s t-test to calculate the statistical significance of difference between groups. The results were presented as the mean value ± SEM. Statistically significant differences were defined as having a P < 0.05.
TMEM158 was overexpressed in ovarian cancer
To further determine TMEM158 expression in ovarian cancer, we performed real-time PCR analysis on 25 pairs of ovarian cancer and their matched noncancerous tissue samples. An overexpression of TMEM158 was found in 84 % (21/25) of tested ovarian cancer tissues (Fig. 1b). Statistical analysis using the student’s t-test showed that TMEM158 mRNA was significantly overexpressed in ovarian tumor tissues when compared with normal tissues (P < 0.001).
TMEM158 was down-regulated by RNA interference (RNAi) in ovarian cancer cells
To investigate the functions of TMEM158 on ovarian cancer, shRNA plasmids were constructed for the suppressing of TMEM158 expression. Three pairs of human TMEM158 gene shRNA sequences and negative control (NC, a non-specific scramble shRNA sequence) were cloned into a lentiviral plasmid. The recombinant lentivirus was packaged in HEK293T cells. HO-8910 and A2780 cells were then infected with TMEM158-RNAi or NC virus. The silencing effect of TMEM158-RNAi were validated in HO-8910 (Fig. 2b) and A2780 cells (Fig. 2c) by Western-blotting and real-time PCR. Our results indicated that TMEM158-Ri-1 was the most efficient one and chosen for the further assays.
Down-regulation of TMEM158 inhibited cell proliferation and induced G1-phase cell cycle arrest in ovarian cancer cells
The possible inhibitory effect of TMEM158 knockdown on cell cycle progression was then determined. As shown in Fig. 3c, downregulation of TMEM158 expression resulted in a higher number of HO-8910 cells in the G1 phase (65.4 % ± 1.5 %), compared with WT cells (42.1 % ± 1.6 %) and NC cells (40.9 % ± 1.2 %). Similar results were observed in A2780 cells (Fig. 3d). Our data suggested that TMEM158 knockdown notably induced G1-phase cell cycle arrest in ovarian cancer cells, which may lead to the inhibition of cell proliferation.
TMEM158 knockdown inhibited cell adhesion
Suppressing TMEM158 expression inhibited the invasiveness of ovarian cancer cells
To explore whether TMEM158 affected the invasive ability of ovarian cancer cells, Matrigel-coated membranes chamber invasion assay was carried out. Dramatically reduced invasive ability was observed in TMEM158 knockdown cells compared to control cells. The number of invaded TMEM158-Ri-1 cells was decreased to 58 % of that of NC cells when HO-8910 cells were used (Fig. 4c and d). Similar results were observed in A2780 cells.
TMEM158 knockdown inhibits ovarian cancer growth in nude mice xenograft model
TMEM158 was positively correlated with TGF-β signaling pathway and cell adhesion molecules
Several investigation have been reported regarding the expression and functions of TMEM158 in different tumors [9–12]. In the present study, analysis using high throughput RNA-sequencing data from TCGA demonstrated a higher expression of TMEM158 in ovarian cancer compared to normal tissues (Fig. 1a). We then found that TMEM158 mRNA expression was elevated in 84 % (21/25) of tested ovarian cancer tissues by real-time PCR (Fig. 1b). To further investigate the functions of TMEM158 in ovarian cancer, we suppressed the expression of TMEM158 in two ovarian cells, HO-8910 and A2780 cells by RNA interference (Fig. 2b and c). Our data showed that suppressing of TMEM158 expression notably inhibited the proliferation, cell cycle progression (Fig. 3), adhesion, invasion (Fig. 4) and tumorigenicity of ovarian cells (Fig. 5). Taken together, our data further indicated contribution of TMEM158 in ovarian cell carcinogenesis.
The regulation of cell cycle is frequently abnormal in most common malignancies, resulting in aberrant cell proliferation [17, 18]. Here, silencing of TMEM158 in ovarian cancer cells significantly promoted cell arrest in G1-phase (Fig. 3c and d), which may lead to the inhibition of cell proliferation (Fig. 3a and b). Our results were consistent with the previous study that found that TMEM158 was an upregulated gene in Ras-senescent human fibroblasts and expected to negatively regulate cell cycle . However, another study indicated that TMEM158-deficient mouse embryonic fibroblasts showed no apparent change in cellular functions, such as proliferation, senescence and oncogenic transformation . The discrepancy may due to differences in cell types and experimental models.
The exact pathway that TMEM158 may regulate in ovarian cancers remains unclear. Our GSEA data indicated that TMEM158 overexpression was positively correlated with the TGF-β signaling pathway (Fig. 6a). As we all known, TGF-β signaling participates in a diverse set of cellular processes, including cell proliferation, differentiation, apoptosis, and specification of developmental fate . The TGF-β signaling pathway has also been considered as a promoter of tumor progression and invasion. In response to elevated TGF-β levels, the tumor cell becomes more migratory and invasive [21, 22]. BMP4 is up-regulated in human colonic adenocarcinoma and human colorectal cancer. HCT116 overexpressing BMP4 exhibited enhanced migration and invasion characteristic . In ovarian cancer, TGF-β and BMP4 are reported to play an important role in controlling ovarian cancer metastasis . In the presents study, TMEM158 knockdown significantly decreased the expression of TGF-β and BMP4 (Fig. 6c and d), which indicated a relation between TMEM158 function and the regulation of TGF-β signaling in ovarian cancer cells.
Moreover, our GSEA data indicated that TMEM158 overexpression was positively correlated with cell adhesion molecules (Fig. 6b). It is reported that serum levels of two important adhesion molecules, ICAM1 and VCAM1 are significant higher in patients with colorectal cancer, ovarian cancer, NSCLC and breast cancer [25–28]. ICAM1 and VCAM1 are considered to be important in the process of malignant tumor growth [26, 29]. In the presents study, TMEM158 knockdown remarkably decreased the mRNA and protein levels of ICAM1 and VCAM1. The dowregulation of ICAM1 and VCAM1 may be associated with the impaired cell-matrix adhesion and invasive ability (Fig. 4) of TMEM158 RNAi cells. To our knowledge, our data firstly associated the functions of TMEM158 with cell adhesion molecules.
Taken together, we found the overexpression of TMEM158 in ovarian cancer cells, which was associated with cancerous transformation. Our study firstly associates TMEM158 with the regulation of cell adhesion molecules and TGF-β signaling pathway, thus may provide useful information for targeted therapy. Whether TMEM158 can be used as a potential therapeutic target for ovarian cancer remains to be further investigated.
We would like to thank JRRUN Biotechnology Co. (Shanghai, China) for their technical assistance for bioinformatics analysis.
- Zeinoun Z, Teugels E, De Bleser PJ, Neyns B, Geerts A, De Greve J. Insufficient TGF-beta 1 production inactivates the autocrine growth suppressive circuit in human ovarian cancer cell lines. Anticancer Res. 1999;19(1a):413–20.PubMedGoogle Scholar
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96. doi:10.3322/CA.2007.0010.PubMedView ArticleGoogle Scholar
- Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni Jr JF. Recent cancer trends in the United States. J Natl Cancer Inst. 1995;87(3):175–82.PubMedView ArticleGoogle Scholar
- Chuffa LGA, Fioruci-Fontanelli BA, Mendes LO, Fávaro WJ, Pinheiro PFF, Martinez M, et al. Characterization of chemically induced ovarian carcinomas in an ethanol-preferring rat model: influence of long-term melatonin treatment. 2013.Google Scholar
- Chuffa LG, Fioruci-Fontanelli BA, Mendes LO, Seiva FRF, Martinez M, Fávaro WJ, et al. Melatonin attenuates the TLR4-mediated inflammatory response through MyD88-and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer. BMC Cancer. 2015;15(1):34.PubMed CentralPubMedView ArticleGoogle Scholar
- Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL. Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model. J Nanobiotechnol. 2015;13(1):25.View ArticleGoogle Scholar
- Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31:14. doi:10.1186/1756-9966-31-14.PubMed CentralPubMedView ArticleGoogle Scholar
- Barradas M, Gonos ES, Zebedee Z, Kolettas E, Petropoulou C, Delgado MD, et al. Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. Exp Cell Res. 2002;273(2):127–37. doi:10.1006/excr.2001.5434.PubMedView ArticleGoogle Scholar
- Sussan TE, Pletcher MT, Murakami Y, Reeves RH. Tumor suppressor in lung cancer 1 (TSLC1) alters tumorigenic growth properties and gene expression. Mol Cancer. 2005;4:28. doi:10.1186/1476-4598-4-28.PubMed CentralPubMedView ArticleGoogle Scholar
- Iglesias D, Fernandez-Peralta AM, Nejda N, Daimiel L, Azcoita MM, Oliart S, et al. RIS1, a gene with trinucleotide repeats, is a target in the mutator pathway of colorectal carcinogenesis. Cancer Genet Cytogenet. 2006;167(2):138–44. doi:10.1016/j.cancergencyto.2005.12.002.PubMedView ArticleGoogle Scholar
- Verlinden I, Janssens J, Raus J, Michiels L. Microdissection and SAGE as a combined tool to reveal gene expression in ductal carcinoma in situ of the breast. Mol Carcinog. 2004;41(4):197–206. doi:10.1002/mc.20055.PubMedView ArticleGoogle Scholar
- Zirn B, Samans B, Wittmann S, Pietsch T, Leuschner I, Graf N, et al. Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes Chromosomes Cancer. 2006;45(6):565–74. doi:10.1002/gcc.20319.PubMedView ArticleGoogle Scholar
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.PubMed CentralPubMedView ArticleGoogle Scholar
- Guo J, Chen L, Luo N, Yang W, Qu X, Cheng Z. Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells. Oncol Rep. 2015;33(6):3124–30.PubMedGoogle Scholar
- Silletti S, Paku S, Raz A. Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization. Int J Cancer. 1998;76(1):120–8.PubMedView ArticleGoogle Scholar
- Yang XJ, Li J, Sun CX, Zheng FY, Hu LN. The effect of high frequency steep pulsed electric fields on in vitro and in vivo antitumor efficiency of ovarian cancer cell line skov3 and potential use in electrochemotherapy. J Exp Clin Cancer Res. 2009;28:53. doi:10.1186/1756-9966-28-53.PubMed CentralPubMedView ArticleGoogle Scholar
- Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–8. doi:10.1038/35077213.PubMedView ArticleGoogle Scholar
- Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 2000;33(5):261–74.PubMedView ArticleGoogle Scholar
- Nieto M, Barradas M, Criado LM, Flores JM, Serrano M, Llano E. Normal cellular senescence and cancer susceptibility in mice genetically deficient in Ras-induced senescence-1 (Ris1). Oncogene. 2007;26(12):1673–80. doi:10.1038/sj.onc.1209978.PubMedView ArticleGoogle Scholar
- Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113(6):685–700.PubMedView ArticleGoogle Scholar
- Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002;12(1):22–9.PubMedView ArticleGoogle Scholar
- Li GC, Ye QH, Dong QZ, Ren N, Jia HL, Qin LX. TGF beta1 and related-Smads contribute to pulmonary metastasis of hepatocellular carcinoma in mice model. J Exp Clin Cancer Res. 2012;31:93. doi:10.1186/1756-9966-31-93.PubMed CentralPubMedView ArticleGoogle Scholar
- Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, Yang WL. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res. 2007;313(5):1033–44. doi:10.1016/j.yexcr.2006.12.020.PubMedView ArticleGoogle Scholar
- Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291(1):59–66. doi:10.1016/j.canlet.2009.09.017.PubMedView ArticleGoogle Scholar
- Staal-van den Brekel AJ, Thunnissen FB, Buurman WA, Wouters EF. Expression of E-selectin, intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 in non-small-cell lung carcinoma. Virchows Arch. 1996;428(1):21–7.PubMedView ArticleGoogle Scholar
- Maurer CA, Friess H, Kretschmann B, Wildi S, Muller C, Graber H, et al. Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int J Cancer. 1998;79(1):76–81.PubMedView ArticleGoogle Scholar
- Banks RE, Gearing AJ, Hemingway IK, Norfolk DR, Perren TJ, Selby PJ. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer. 1993;68(1):122–4.PubMed CentralPubMedView ArticleGoogle Scholar
- Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Bramis I, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer. 2001;37(18):2392–7.PubMedView ArticleGoogle Scholar
- Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 2005;26(5):943–50. doi:10.1093/carcin/bgi070.PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.